EDUCATION > Courses and Products > E-Learning > Videos/Webcasts > 2013 Annual Meeting Webcasts > Prostate Cancer > Module 4: Managing Metastatic Prostate Cancer in Your Urology Practice: Coding and Science

Module 4: Managing Metastatic Prostate Cancer in Your Urology Practice: Coding and Science

Introduction/Activity Overview Statement of Need

The course will discuss in detail the indications and use, coding aspects and provide necessary information to begin using the novel agents approved for use within the last 2 years to treat patients with metastatic prostate cancer by practicing urologists in their offices.

Learning Objectives

After participating in this activity, participants should be able to:

  • select correct agents for use in management of patients with metastatic prostate cancer
  • describe risks and benefits of the agent to patients with metastatic prostate cancer
  • identify coding and administrative issues associated with use of the novel agents in urology office practice

Faculty/Authors Disclosures

K.C. Balaji, MD, Director
Chief of Urology/Professor, Urology Cancer Biology
Wake Forest University School of Medicine
Winston Salem, NC

Ronald L. Davis, III, MD, Faculty
Associate Professor of Urology
Wake Forest University Baptist Health
Winston-Salem, NC

Name

Company

Relationship

Financial

K.C. Balaji, MD Sanofi Aventis Meeting Participant or Lecturer Yes
       
Ronald L. Davis, III, MD Nothing to Disclose    
       

Acknowledgement for Support

Support provided by educational grants from the following companies:

Abbvir Algeta AMGEN Astellas
Bayer Janseen Medivation Millennium

K.C. Balaji, MD
Coding and Science of Managing Metastatic Prostate Cancer by Urologists


Ronald L. Davis, III, MD
Introduction to the Business of Medicine

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT